EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study

Jung Sun Kim, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Jung Yong Hong, Ho Yeong Lim, Han Sang Kim, Chang Gon Kim, Sanghoon Jung iD, Chansik An iD und 2 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70997 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jung Sun Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: Liver Neoplasms, Nivolumab, Ipilimumab, Carcinoma, Hepatocellular. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, considering prior ICI exposure, compared with nivolumab (Nivo) monotherapy.

Methods

We analyzed 204 lesions from Nivo/Ipi‐treated and 305 lesions from Nivo‐treated patients with advanced HCC at five referral cancer centers in Korea. Organ‐specific response criteria were adopted from Response Evaluation Criteria in Solid Tumors 1.1, according to the indicated sites: the liver, lung, lymph nodes (LNs), and other metastatic sites.

Results

Nivo/Ipi combination therapy showed OSORRs of 18.1% in the liver, 17.7% in the lungs, 30.0% in LNs, and 12.5% in other metastatic sites. Patients without prior ICI exposure had OSORRs of 29.0% in the liver, 31.3% in the lungs, 33.3% in LNs, and 23.1% in other metastatic sites (72 individual lesions). Conversely, patients with prior ICI exposure had OSORRs of 11.5% in the liver, 11.4% in the lung, 27.8% in LNs, and 7.4% in other metastatic sites (132 individual lesions). Furthermore, patients who achieved a response in the liver or the lung had longer progression‐free and overall survival, compared with those without responses. Nivo monotherapy yielded OSORRs of 13.5%, 25.3%, 39.3%, and 18.4% in the liver, lungs, LNs, and other metastatic sites, respectively.

Conclusion

Nivo/Ipi combination therapy induced superior intrahepatic responses compared to Nivo monotherapy in patients with advanced HCC without prior ICI exposure, highlighting its potential to overcome liver‐specific immune tolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsNivolumabIpilimumabCarcinoma, HepatocellularAntineoplastic Combined Chemotherapy ProtocolsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedAdultImmune Checkpoint InhibitorsAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Nivolumab monotherapyNivolumab plus ipilimumabadvanced HCCimmune checkpoint inhibitororgan‐specific objective response rateprior ICI treatment

Substanzen

NivolumabIpilimumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
  • CHA University School of Medicine, Seongnam, Korea.
  • Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

ORCID-Profile: Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Kim, J. S., Kim, Y., Kang, B., Kim, I., Kim, H., Lee, W. S., Hong, J. Y., Lim, H. Y., Kim, H. S., Kim, C. G., Jung, S., An, C., Kim, C., & Chon, H. J. (2025). Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study. Cancer Medicine. https://doi.org/10.1002/cam4.70997

Vancouver

Kim JS, Kim Y, Kang B, Kim I, Kim H, Lee WS, et al. Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study. Cancer Medicine. 2025. doi:10.1002/cam4.70997

BibTeX
@article{Kim2025,
  author = {Kim, Jung Sun and Kim, Youngun and Kang, Beodeul and Kim, Ilhwan and Kim, Hyeyeong and Lee, Won Suk and Hong, Jung Yong and Lim, Ho Yeong and Kim, Han Sang and Kim, Chang Gon and Jung, Sanghoon and An, Chansik and Kim, Chan and Chon, Hong Jae},
  title = {Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70997}
}
Kostenlos starten →